Matthijs J. Scheltema

Treatment Outcomes from ⁶⁸Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET

Louise Emmett, Pim J. van Leeuwen, Rohan Nandurkar et al. · Journal of Nuclear Medicine · 2017 · 183 citations

Medicine, Nuclear Medicine, Urology +17

Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project

Kae Jack Tay, Matthijs J. Scheltema, Hashim U. Ahmed et al. · Prostate Cancer and Prostatic Diseases · 2017 · 149 citations

Medicine, Radiation Oncology, Urology +12

3-Year Freedom from Progression After ⁶⁸Ga-PSMA PET/CT–Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial

Louise Emmett, Reuben Tang, Rohan Nandurkar et al. · Journal of Nuclear Medicine · 2019 · 148 citations · Full text

Medicine, Nuclear Medicine, Urology +17

Focal irreversible electroporation as primary treatment for localized prostate cancer

Willemien van den Bos, Matthijs J. Scheltema, Amila Siriwardana et al. · British Journal of Urology · 2017 · 120 citations · Full text

Medicine, Oncology, Urology +17

Diagnostic accuracy of ⁶⁸ Ga‐prostate‐specific membrane antigen ( <scp>PSMA</scp> ) positron‐emission tomography ( <scp>PET</scp> ) and multiparametric (mp) <scp>MRI</scp> to detect intermediate‐grade intra‐prostatic prostate cancer using whole‐mount pathology: impact of the addition of ⁶⁸ Ga‐ <scp>PSMA PET</scp> to mp <scp>MRI</scp>

Matthijs J. Scheltema, John Chang, Phillip D. Stricker et al. · British Journal of Urology · 2019 · 116 citations · Full text

Medicine, Nuclear Medicine, Urology +17